Economics, health-related quality of life, and cost-effectiveness methods for the TACTICS (Treat Angina With Aggrastat [tirofiban]] and Determine Cost of Therapy with Invasive or Conservative Strategy)-TIMI 18 trial.

[1]  R. Califf,et al.  Economic assessment of low-molecular-weight heparin (enoxaparin) versus unfractionated heparin in acute coronary syndrome patients: results from the ESSENCE randomized trial. Efficacy and Safety of Subcutaneous Enoxaparin in Non-Q wave Coronary Events [unstable angina or non-Q-wave myocardial infarc , 1998, Circulation.

[2]  W. Weintraub,et al.  A study on the cost-effectiveness of coronary revascularization: introducing the simultaneous mimic health status model. , 1997, Health Economics.

[3]  T. Investigators.  Effects of platelet glycoprotein IIb/IIIa blockade with tirofiban on adverse cardiac events in patients with unstable angina or acute myocardial infarction undergoing coronary angioplasty. The RESTORE Investigators. Randomized Efficacy Study of Tirofiban for Outcomes and REstenosis. , 1997, Circulation.

[4]  W. Weintraub,et al.  Economic winners and losers after introduction of an effective new therapy depend on the type of payment system. , 1997, The American journal of managed care.

[5]  J. O’Keefe,et al.  Analysis of the relative costs and effectiveness of primary angioplasty versus tissue-type plasminogen activator: the Primary Angioplasty in Myocardial Infarction (PAMI) trial. The PAMI Trial Investigators. , 1997, Journal of the American College of Cardiology.

[6]  M. Johannesson,et al.  Cost effectiveness of simvastatin treatment to lower cholesterol levels in patients with coronary heart disease. Scandinavian Simvastatin Survival Study Group. , 1997, The New England journal of medicine.

[7]  E J Topol,et al.  Economic assessment of platelet glycoprotein IIb/IIIa inhibition for prevention of ischemic complications of high-risk coronary angioplasty. EPIC Investigators. , 1996, Circulation.

[8]  B. Spilker,et al.  Quality of life and pharmacoeconomics in clinical trials , 1996 .

[9]  A S Kosinski,et al.  A comparison of the costs of and quality of life after coronary angioplasty or coronary surgery for multivessel coronary artery disease. Results from the Emory Angioplasty Versus Surgery Trial (EAST). , 1995, Circulation.

[10]  H. Suryapranata,et al.  A cost-effective analysis of primary coronary angioplasty versus thrombolysis for acute myocardial infarction. , 1995, The American journal of cardiology.

[11]  L. Goldman,et al.  Cost-effectiveness of captopril therapy after myocardial infarction. , 1995, Journal of the American College of Cardiology.

[12]  L. Goldman,et al.  Cost and quality of life: thrombolysis and primary angioplasty. , 1995, Journal of the American College of Cardiology.

[13]  Erry,et al.  Cost effectiveness of thrombolytic therapy with tissue plasminogen activator as compared with streptokinase for acute myocardial infarction. , 1995, The New England journal of medicine.

[14]  Conti Cr.  Editor's note: Unstable angina: Cost of conservative and invasive strategies using timi 3 b as a model , 1995 .

[15]  J. Deckers,et al.  Costs and effects of long-term oral anticoagulant treatment after myocardial infarction. , 1995, JAMA.

[16]  J. Spertus,et al.  Monitoring the quality of life in patients with coronary artery disease. , 1994, The American journal of cardiology.

[17]  S. Pauker,et al.  Cost-effectiveness of streptokinase for acute myocardial infarction: A combined meta-analysis and decision analysis of the effects of infarct location and of likelihood of infarction. , 1994, Medical decision making.

[18]  M. Weinstein,et al.  Cost-effectiveness of a smoking cessation program after myocardial infarction. , 1993, Journal of the American College of Cardiology.

[19]  N. Frasure-smith,et al.  Depression following myocardial infarction. Impact on 6-month survival. , 1993, JAMA.

[20]  A. Dobson,et al.  Secondary prevention after acute myocardial infarction. , 1993, The American journal of cardiology.

[21]  G. Guyatt,et al.  Economic evaluation of cardiac rehabilitation soon after acute myocardial infarction , 1993 .

[22]  Harlan M. Krumholz,et al.  Cost effectiveness of thrombolytic therapy with streptokinase in elderly patients with suspected acute myocardial infarction. , 1992, The New England journal of medicine.

[23]  R. Robinson,et al.  Depression following Myocardial Infarction , 1992, International journal of psychiatry in medicine.

[24]  V S Conn,et al.  Anxiety, depression, quality of life, and self-care among survivors of myocardial infarction. , 1991, Issues in mental health nursing.

[25]  W C Hsiao,et al.  Estimating physicians' work for a resource-based relative-value scale. , 1988, The New England journal of medicine.

[26]  E F Cook,et al.  Costs and effectiveness of routine therapy with long-term beta-adrenergic antagonists after acute myocardial infarction. , 1988, The New England journal of medicine.

[27]  J. Rutherford,et al.  Unstable Angina , 1990, Springer Berlin Heidelberg.